无锡祥生医疗科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688358 证券简称：祥生医疗 无锡祥生医疗科技股份有限公司 2024 年年度股东大会会议须知 无锡祥生医疗科技股份有限公司 2024 年年度股东大会 会议资料 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保 证大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 二〇二五年五月 1 无锡祥生医疗科技股份有限公司 2024 年年度股东大会会议资料 四、股东及股东代理人参加股东大会依法享有发言权、质询权、表决权等 权利。股东及股东代理人参加股东大会应认真履行其法定义务，不得侵犯公司 和其他股东及股东代理人的合法权益，不得扰乱股东大会的正常秩序。 五、股东及股东代理人要求在股东大会现场会议上发言的，应于股东大会 召开前一天向大会会务组进行登记。大会主持人根据会务组提供的名单和顺序 安排发言。 现场要求提问的股东及股东代理人，应当按照会议的议程举手示意，经会 议主持人许可后方可提问。有多名股东及股东代理人同时要求提问时，先举手 者先提问；不能确定先后时，由主持人指定提问者。 会议进行中只接受股东及股东代理人 ...

Group 1 - The core stock price of Xiangsheng Medical (688358) closed at 28.78 yuan on April 30, 2025, with an increase of 2.53% and a trading volume of 1.09 million shares, resulting in a transaction amount of 31.428 million yuan [1] - The company has made significant advancements in AI-assisted diagnostic software across various medical fields, including breast diseases, carotid arteries, thyroid, obstetrics, liver, and heart [2] - On April 30, 2025, the net capital flow for Xiangsheng Medical showed a net outflow of 76.25 thousand yuan from main funds, a net outflow of 49.76 thousand yuan from speculative funds, while retail investors had a net inflow of 126.01 thousand yuan [2] Group 2 - The company is committed to continuous technological and product innovation, aiming to accelerate the integration of AI technology in ultrasound medical imaging and diagnosis [2] - The capital flow analysis indicates that main funds accounted for 2.43% of the total transaction amount, speculative funds accounted for 1.58%, and retail investors represented 4.01% [2]

Group 1: Company Insights - BGI Genomics faces challenges such as declining demand, operational complexity, and high prices in the genetic testing industry, but is enhancing efficiency through automation and AI, while expanding into reproductive health and cancer prevention [1] - Nanshan Zhishang reported a 12.84% year-on-year increase in net profit for Q1, driven by new materials business, particularly ultra-high molecular weight polyethylene fibers [2] - Jizhi Co. saw a 54.89% increase in revenue year-on-year in Q1, benefiting from stable growth in balancing machine sales and automation line revenue [3] - Huangma Technology's export sales grew over 30% in Q1 2025, with improved gross margins due to increased production and lower raw material costs [4] - Proya Cosmetics aims to become the first beauty company in China to exceed 10 billion in revenue by 2024, focusing on expanding its product matrix and enhancing online and offline channels [5] - Daotong Technology is advancing its "embrace AI" strategy, significantly enhancing its digital repair and energy products, with a 60% growth in its TPMS series [6] - Lianchuang Optoelectronics experienced significant revenue growth in Q1 2025, with a focus on optimizing asset quality in the backlight source industry [7] - Hengshuai Co. reported a 16.04% decline in revenue for Q1 2025, facing challenges in traditional cleaning and motor businesses, but is expanding its ADAS cleaning system business [8] - Weifeng Electronics achieved a 9.77% revenue growth in 2024, despite a decline in net profit due to reduced non-operating income and increased expenses [9] - Perfect World continues to enhance its gaming portfolio with successful updates and expansions, including the launch of new titles and esports initiatives [11] - Xiangsheng Medical invested 80 million in R&D in 2024, focusing on AI technology in ultrasound products and maintaining a strong dividend policy [12] - Jiuhua Tourism reported a 30.13% revenue increase in Q1 2025, driven by a rise in tourist visits and ongoing infrastructure projects [13] - Jingzhida's semiconductor business line saw a revenue share increase to over 70% in Q1 2025, with ongoing efforts to localize core components [14] - Teruid's management outlined plans for international expansion and the development of a virtual power plant platform to enhance service offerings [15] Group 2: Industry Trends - The genetic testing industry is experiencing increased competition and cost pressures, prompting companies to innovate and optimize operations [1] - The new materials sector is becoming a key growth driver, particularly in high-performance fibers used in various applications [2] - Automation and AI are reshaping traditional manufacturing and service sectors, enhancing efficiency and product offerings [3][6] - The beauty and cosmetics industry is focusing on market expansion and product diversification to capture a larger share of the global market [5] - The gaming industry is evolving with continuous updates and new releases, indicating a strong demand for innovative gaming experiences [11] - The tourism sector is recovering with increased visitor numbers, highlighting the importance of infrastructure development and service enhancement [13]

Investment Rating - The investment rating for Xiangsheng Medical (688358) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on revenue growth and product development [1]. Core Viewpoints - The company reported a revenue of 469 million yuan in 2024, a year-over-year decrease of 3.13%, with a net profit of 141 million yuan, down 4.08% year-over-year. However, cash flow from operating activities increased significantly by 63.76% to 141 million yuan [1][2]. - The company maintains a stable gross margin of 58.95% in 2024, slightly up from the previous year, attributed to an increase in domestic sales and changes in product structure [2]. - Research and development efforts are focused on AI advancements, enhancing the competitiveness of portable ultrasound products, and addressing clinical pain points with innovative solutions [2]. Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 469 million yuan, with ultrasound imaging equipment contributing 427 million yuan and accessories generating 30.4 million yuan, reflecting a 20.45% increase year-over-year [2]. - The company’s gross margin for 2024 was 58.95%, showing a slight increase of 0.14 percentage points year-over-year [2]. - The forecast for revenue from 2025 to 2027 is 549 million yuan, 664 million yuan, and 801 million yuan, with respective year-over-year growth rates of 17.0%, 21.0%, and 20.8% [2][4]. Research and Development - R&D expenses reached 79.63 million yuan in 2024, representing 16.99% of total revenue, indicating a strong commitment to innovation [2]. - The company has made significant progress in AI-assisted diagnostic software across various medical fields, enhancing the accuracy and efficiency of screenings [2]. Market Position and Strategy - The company is actively expanding its market presence, particularly in the domestic sector, benefiting from government policies aimed at upgrading medical equipment [2]. - The report highlights the company's strategic focus on portable ultrasound technology, which is expected to drive future growth and customer acquisition [2].

Investment Rating - The investment rating for Xiangsheng Medical (688358) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on revenue growth and product development [1]. Core Viewpoints - The company reported a revenue of 469 million yuan in 2024, a year-over-year decrease of 3.13%, with a net profit of 141 million yuan, down 4.08% year-over-year. However, cash flow from operating activities increased significantly by 63.76% to 141 million yuan [1][2]. - The company maintains a stable gross margin of 58.95% in 2024, slightly up from the previous year, attributed to an increase in domestic sales and changes in product structure [2]. - Research and development efforts are focused on AI advancements, enhancing the competitiveness of portable ultrasound products, and addressing clinical pain points with innovative solutions [2]. Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 469 million yuan, with ultrasound imaging equipment contributing 427 million yuan and accessories 30.4 million yuan. The technical service revenue saw a significant decline of 49.65% to 10.64 million yuan [2]. - The company’s gross margin for 2024 was 58.95%, reflecting a slight increase of 0.14 percentage points year-over-year [2][4]. - The projected revenues for 2025 to 2027 are 549 million yuan, 664 million yuan, and 801 million yuan, respectively, with year-over-year growth rates of 17.0%, 21.0%, and 20.8% [2][4]. Research and Development - The company invested 79.63 million yuan in R&D in 2024, representing 16.99% of its revenue, focusing on the SonoFamily product line and AI-assisted diagnostic software [2]. - Innovations include the SonoAir series, which has gained recognition for its advanced imaging technology and design, and the development of AI-driven solutions for breast cancer screening [2]. Market Position and Strategy - The company is actively expanding its market presence, particularly in the domestic sector, benefiting from policies like "old-for-new" exchanges to enhance its foothold in grassroots medical markets [2]. - Despite a 4% decline in overseas revenue due to global economic conditions, domestic revenue grew by 6.21% to 62.86 million yuan [2].

Group 1 - Haiyuan Composite will implement delisting risk warning from April 29, 2025, with stock name changed to "*ST Haiyuan" and daily price fluctuation limit set at 5% [3] - Xinlaifu plans to acquire 100% of Jin Nan Magnetic Materials, with the transaction expected to constitute a major asset restructuring, and stock will resume trading on April 28, 2025 [4] - Hongbaoli's subsidiary successfully completed trial production of polyether technology transformation project, producing qualified products [5] - Xingguang Co. received a warning letter from Guangdong Securities Regulatory Bureau due to significant discrepancies in 2024 performance forecast and actual results [6] - Meirui New Materials' subsidiary successfully completed the production process for its polyurethane industrial park phase one project [7] Group 2 - Taigang Stainless Steel reported Q1 2025 net profit of 188 million yuan, a year-on-year increase of 5506.92%, with revenue of 23.31 billion yuan, down 4.71% [9] - Shen Shen Fang A reported Q1 2025 net profit of 72.42 million yuan, a year-on-year increase of 3718.51%, with revenue of 330 million yuan, up 457.38% [10] - Qingda Environmental reported Q1 2025 net profit of 68.71 million yuan, a year-on-year increase of 990.26%, with revenue of 619 million yuan, up 317.43% [11] - Jincai Hulin reported Q1 2025 net profit of 13.65 million yuan, a year-on-year increase of 466.95%, with revenue of 206 million yuan, down 33% [13] - New Sai Co. reported Q1 2025 net profit of 18.19 million yuan, a year-on-year increase of 315.74%, with revenue of 1.215 billion yuan, up 312.03% [14] - Kexing Pharmaceutical reported Q1 2025 net profit of 25.58 million yuan, a year-on-year increase of 106.21%, with revenue of 354 million yuan, down 1.97% [15] - Jiechang Drive reported Q1 2025 net profit of 113 million yuan, a year-on-year increase of 62.21%, with revenue of 961 million yuan, up 35.59% [16] - Taihe Co. reported Q1 2025 net profit of 78.53 million yuan, a year-on-year increase of 50.94%, with revenue of 1.033 billion yuan, up 18.5% [17] - Xiyu Co. reported Q1 2025 net profit of 499 million yuan, a year-on-year increase of 53.08%, with revenue of 9.729 billion yuan, up 15.82% [18] - Hualing Cable reported Q1 2025 net profit of 32.16 million yuan, a year-on-year increase of 55.54%, with revenue of 1.005 billion yuan, up 11.38% [19] - Dong'a Ejiao reported Q1 2025 net profit of 425 million yuan, a year-on-year increase of 20.25%, with revenue of 1.719 billion yuan, up 18.24% [20] - China Rare Earth reported Q1 2025 net profit of 72.62 million yuan, turning from loss to profit, with revenue of 728 million yuan, up 141.32% [21] - Gree Electric reported 2024 net profit of 32.185 billion yuan, a year-on-year increase of 10.91%, with revenue of 189.164 billion yuan, down 7.26% [22] - Luzhou Laojiao reported 2024 net profit of 13.473 billion yuan, a year-on-year increase of 1.71%, with revenue of 31.196 billion yuan, up 3.19% [24] - Yake Technology reported 2024 net profit of 872 million yuan, a year-on-year increase of 50.41%, with revenue of 6.862 billion yuan, up 44.84% [25] - Gujing Gongjiu reported 2024 net profit of 5.517 billion yuan, a year-on-year increase of 20.22%, with revenue of 23.578 billion yuan, up 16.41% [26] - Lanzhou Bank reported 2024 net profit of 1.888 billion yuan, a year-on-year increase of 1.29%, with revenue of 7.854 billion yuan, down 2.02% [27] - China Power Construction reported 2024 net profit of 12.015 billion yuan, a year-on-year decrease of 7.21%, with revenue of 633.685 billion yuan, up 4.07% [28] - China Communications Construction reported Q1 2025 net profit of 5.467 billion yuan, a year-on-year decrease of 10.98%, with revenue of 154.644 billion yuan, down 12.58% [29] Group 3 - Koweil plans to reduce its shareholding by up to 3.21% [31] - Nanya New Materials plans to reduce its repurchased shares by up to 238,480 shares, accounting for 1% of total shares [32] - Xiangsheng Medical's shareholders plan to reduce their holdings by up to 1.72% [33] Group 4 - Zhenhua Heavy Industry plans to repurchase shares worth 50 million to 100 million yuan [35] - Deep Keda plans to acquire 16.92% of the equity of its subsidiary Xianma Technology for 47.376 million yuan [37] - Jinchengxin signed a mining production contract with Western Mining, with an estimated contract value of approximately 377 million yuan [38]

格隆汇4月27日丨祥生医疗(688358.SH)公布，因股东自身资金需求及资金规划，公司股东无锡祥鼎投资 企业（有限合伙）、拟自本减持计划公告披露之日起15个交易日后的3个月内，通过集中竞价或大宗交 易的方式减持合计不超过所持公司股份1,176,000股,即不超过祥生医疗总股本的1.05%。其中以集中竞价 方式拟减持股份数量为合计不超过701,256股，即不超过祥生医疗总股本的0.63%；以大宗交易方式拟减 持股份数量为合计不超过474,744股，即不超过祥生医疗总股本的0.42%。 因股东自身资金需求及资金规划，公司股东上海御德科技有限公司拟自本减持计划公告披露之日起15个 交易日后的3个月内，通过集中竞价的方式减持合计不超过所持公司股份419,989股,即不超过公司总股本 的0.37%。 因股东自身资金需求及资金规划，公司股东无锡祥鹏投资企业（有限合伙）拟自本减持计划公告披露之 日起15个交易日后的3个月内，通过集中竞价的方式减持合计不超过所持公司股份336,000股,即不超过公 司总股本的0.30%。 上述股东减持价格将根据减持时的市场价格确定；若在减持计划实施期间公司发生送股、资本公积转增 股本、配股 ...

Core Viewpoint - Xiangsheng Medical has demonstrated significant advancements in AI-assisted ultrasound diagnostics, showcasing a strong financial performance and a robust innovation pipeline in the healthcare sector [1][2][3] Financial Performance - In Q1 2025, the company reported revenue of 128 million yuan and a net profit of 41.61 million yuan attributed to shareholders [1] Technological Advancements - The company has made breakthroughs in AI-assisted diagnostic software across multiple specialties, with a notable achievement being the breast ultrasound analysis software, which received medical device registration in 2022 [2] - As of the end of 2024, the company holds a total of 61 core technologies, reflecting its leading position in independent innovation within the industry [2] Research and Development - In 2024, the company invested 79.63 million yuan in R&D, accounting for 16.99% of its revenue, with R&D personnel making up 34.64% of its workforce [2] - The company secured 48 new patent authorizations in 2024, including 30 invention patents, and filed 66 intellectual property applications [2] Product Development - The company launched the SonoFamily series in 2024, which includes various high-end ultrasound products, enhancing its market offerings [3] - In 2024, the company obtained 5 domestic market access licenses and 35 international market access licenses, expanding its global presence [3] Market Positioning - Driven by domestic policy benefits and global market demand, the company is solidifying its leadership in the specialty ultrasound field, with a focus on the deep application of medical AI to accelerate industry transformation [3]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-015 无锡祥生医疗科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ⚫ 本次减持股东的基本情况 截至本公告披露日，无锡祥生医疗科技股份有限公司（以下简称"公司"）股 东无锡祥鼎投资企业（有限合伙）（以下简称"祥鼎投资"）持有公司股份 4,704,000 股，占公司总股本的 4.20%；股东上海御德科技有限公司（以下简称"上海御德"） 持有公司股份 1,679,956 股，占公司总股本的 1.50%；股东无锡祥鹏投资企业（有 限合伙）（以下简称"祥鹏投资"）持有公司股份 1,344,000 股，占公司总股本的 1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份，涉及公司首次公开发行前取得的股份已于 2022 年 12 月 3 日解除限售并上市流通。 ⚫ 减持计划的主要内容 因股东自身资金需求及资金规划，公司股东无锡祥鼎投资企业（有限 ...

Core Viewpoint - Wuxi Xiangsheng Medical Technology Co., Ltd. reported strong financial performance for 2024 and Q1 2025, indicating significant growth and innovation in the ultrasound medical equipment sector [1][2]. Financial Performance - In 2024, the company achieved a revenue of 469 million yuan and a net profit of 141 million yuan attributable to shareholders [1]. - The fourth quarter of 2024 saw a revenue of 106 million yuan, a year-on-year increase of 29.77%, and a net profit of approximately 42.1 million yuan, reflecting a quarter-on-quarter growth of 146.69% and a year-on-year increase of 733.85% [1]. - For Q1 2025, the company reported a revenue of 128 million yuan, a quarter-on-quarter increase of 19.97%, and a net profit of approximately 41.6 million yuan [1]. Product Innovation and Development - The company launched the SonoFamily series, which includes high-end ultrasound products such as XBit, SonoMax, SonoAir, and SonoEye, aimed at enhancing market presence [1]. - In 2024, the company accelerated the registration of products domestically and internationally, adding five new domestic market access licenses and achieving a total of 35 licenses across various regions [2]. - Research and development investment reached approximately 79.6 million yuan in 2024, representing 16.99% of revenue, with a total of 151 invention patents held by the company [2]. AI Technology Integration - The company has been exploring AI technology since 2016, leading to the development of SonoAI, which has made significant advancements in AI-assisted diagnostic software for various medical fields [2]. - Achievements include dynamic image recognition, automatic disease detection, and optimization of diagnostic processes, establishing a comprehensive ultrasound AI technology ecosystem [2]. Dividend Policy - The company proposed a cash dividend of 10 yuan per 10 shares, totaling approximately 112 million yuan, which constitutes 79.62% of the net profit for the year [3]. - Since its listing in 2019, the company has maintained an average dividend payout ratio of 61.71%, with cumulative dividends amounting to 464 million yuan, reflecting confidence in future growth [3].